Business Description
![Carl Zeiss Meditec AG Carl Zeiss Meditec AG logo](https://static.gurufocus.com/logos/0C00000UBK.png?14)
Carl Zeiss Meditec AG
ISIN : DE0005313704
Share Class Description:
LTS:0DHC: Ordinary SharesCompare
Compare
Traded in other countries / regions
AFX.Germany0DHC.UKCZMWY.USA1AFX.ItalyAFX.AustriaAFX.SwitzerlandAFX.Mexico IPO Date
2007-12-14Description
Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.24 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.37 | |||||
Interest Coverage | 17 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.65 | |||||
Beneish M-Score | -2.15 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.1 | |||||
3-Year EBITDA Growth Rate | 23.4 | |||||
3-Year EPS without NRI Growth Rate | 33.4 | |||||
3-Year FCF Growth Rate | 0.9 | |||||
3-Year Book Growth Rate | 14.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.17 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.35 | |||||
9-Day RSI | 26.72 | |||||
14-Day RSI | 25.51 | |||||
6-1 Month Momentum % | -9.11 | |||||
12-1 Month Momentum % | -15.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.51 | |||||
Quick Ratio | 2.41 | |||||
Cash Ratio | 0.07 | |||||
Days Inventory | 204.91 | |||||
Days Sales Outstanding | 55.28 | |||||
Days Payable | 83.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.69 | |||||
Dividend Payout Ratio | 0.38 | |||||
3-Year Dividend Growth Rate | 19.2 | |||||
Forward Dividend Yield % | 1.69 | |||||
5-Year Yield-on-Cost % | 3.28 | |||||
Shareholder Yield % | 2.03 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 56.32 | |||||
Operating Margin % | 15.15 | |||||
Net Margin % | 12.67 | |||||
FCF Margin % | 2.92 | |||||
ROE % | 12.61 | |||||
ROA % | 9.02 | |||||
ROIC % | 8.4 | |||||
ROC (Joel Greenblatt) % | 54.47 | |||||
ROCE % | 16.39 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 22.32 | |||||
Forward PE Ratio | 22.47 | |||||
PE Ratio without NRI | 22.32 | |||||
Shiller PE Ratio | 30.76 | |||||
PEG Ratio | 1.14 | |||||
PS Ratio | 2.83 | |||||
PB Ratio | 2.79 | |||||
Price-to-Tangible-Book | 4.15 | |||||
Price-to-Free-Cash-Flow | 97.03 | |||||
Price-to-Operating-Cash-Flow | 97.03 | |||||
EV-to-EBIT | 15.31 | |||||
EV-to-Forward-EBIT | 16.6 | |||||
EV-to-EBITDA | 15.31 | |||||
EV-to-Forward-EBITDA | 13.43 | |||||
EV-to-Revenue | 2.89 | |||||
EV-to-Forward-Revenue | 2.56 | |||||
EV-to-FCF | 98.93 | |||||
Price-to-Projected-FCF | 1.26 | |||||
Price-to-DCF (Earnings Based) | 0.91 | |||||
Price-to-DCF (FCF Based) | 7.16 | |||||
Price-to-Median-PS-Value | 0.6 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.17 | |||||
Price-to-Graham-Number | 2.03 | |||||
Price-to-Net-Current-Asset-Value | 6.13 | |||||
Earnings Yield (Greenblatt) % | 6.53 | |||||
FCF Yield % | 1.03 | |||||
Forward Rate of Return (Yacktman) % | 22.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Carl Zeiss Meditec AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,061.946 | ||
EPS (TTM) (€) | 2.93 | ||
Beta | 1.77 | ||
Volatility % | 36.38 | ||
14-Day RSI | 25.51 | ||
14-Day ATR (€) | 2.608208 | ||
20-Day SMA (€) | 71.04375 | ||
12-1 Month Momentum % | -15.67 | ||
52-Week Range (€) | 62.5 - 123.3 | ||
Shares Outstanding (Mil) | 89.44 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Carl Zeiss Meditec AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Carl Zeiss Meditec AG Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Carl Zeiss Meditec AG Frequently Asked Questions
What is Carl Zeiss Meditec AG(LTS:0DHC)'s stock price today?
The current price of LTS:0DHC is €65.28. The 52 week high of LTS:0DHC is €123.30 and 52 week low is €62.50.
When is next earnings date of Carl Zeiss Meditec AG(LTS:0DHC)?
The next earnings date of Carl Zeiss Meditec AG(LTS:0DHC) is 2024-08-06.
Does Carl Zeiss Meditec AG(LTS:0DHC) pay dividends? If so, how much?
The Dividend Yield %  of Carl Zeiss Meditec AG(LTS:0DHC) is 1.69% (As of Today), Highest Dividend Payout Ratio of Carl Zeiss Meditec AG(LTS:0DHC) was 0.49. The lowest was 0.19. And the median was 0.33. The  Forward Dividend Yield % of Carl Zeiss Meditec AG(LTS:0DHC) is 1.69%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |